Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVXâ„¢ (suzetrigine), an oral, non-opioid, highly selective ...
The FDA has accepted for Priority Review the NDA for vatiquinone for the treatment of children and adults living with Friedreich ataxia.